Regulation of androgen receptor signaling in prostate cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 1, 2005, Pages 63-74

  Dehm, Scott M ^a   Tindall, Donald J ^a  

^a Mayo Clinic   (United States)

Author keywords

Androgen receptor; Hormone refractory; Prostate cancer; Transcription

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; BICALUTAMIDE; CELL CYCLE PROTEIN 37; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 8; CYPROTERONE ACETATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR BETA; FINASTERIDE; FLUTAMIDE; GONADORELIN; HEAT SHOCK PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; HORMONE BINDING PROTEIN; HYPOTHALAMUS RELEASE INHIBITING FACTOR; LUTEINIZING HORMONE; MESSENGER RNA; MIFEPRISTONE; PRASTERONE; PROTEIN P160; PROTEIN P300; PROTEIN P85; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; UNINDEXED DRUG;

ANDROGEN INSENSITIVITY SYNDROME; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RISK; CASTRATION; CLINICAL TRIAL; CORRELATION FUNCTION; DISEASE COURSE; DNA MICROARRAY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HORMONAL CARCINOGENESIS; HORMONE BINDING; HORMONE RECEPTOR INTERACTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUTEINIZING HORMONE RELEASE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE RAS; ONCOGENE SRC; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIZATION; SERIAL ANALYSIS OF GENE EXPRESSION; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TRANSCRIPTION REGULATION; TREATMENT FAILURE;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 14244254699     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.1.63     Document Type: Review

References (96)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin. 53(1), 5-26 (2003).
2. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 61(2 Suppl. 1), 14-24 (2003).
3. Hammond GL, Avvakumov GV, Muller YA. Structure/function analyses of human sex hormone-binding globulin: effects of zinc on steroid-binding specificity. J. Steroid Biochem. Mol. Biol. 85(2-5), 195-200 (2003).
4. Lamb DJ, Weigel NL, Marcelli M. Androgen receptors and their biology. Vitam. Horm. 62, 199-230 (2001).
5. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol. Endocrinol. 9(2), 208-218 (1995).
6. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18(3), 306-360 (1997).
7. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 9(3), 601-610 (2002).
8. Naar AM, Lemon BD, Tjian R. Transcriptional coactivator complexes. Ann. Rev. Biochem. 70, 475-501 (2001).
9. Migliaccio A, Castoria G, Di Domenico M et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J. 19(20), 5406-5417 (2000).
10. Kousteni S, Bellido T, Plotkin LI et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104(5), 719-730 (2001).
11. Kousteni S, Han L, Chen JR et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111(11), 1651-1664 (2003).
12. Unni E, Sun S, Nan B et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64(19), 7156-7168 (2004).
13. Castoria G, Lombardi M, Barone MV et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J. Cell Biol. 161(3), 547-556 (2003).
14. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70(9-10), 506-521 (2002).
15. DePrimo SE, Diehn M, Nelson JB et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 3(7), RESEARCH0032 (2002).
16. Nelson PS, Clegg N, Arnold H et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl Acad. Sci. USA 99(18), 11890-11895 (2002).
17. Velasco AM, Gillis KA, Li Y et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145(8), 3913-3924 (2004).
18. Segawa T, Nau ME, Xu LL et al. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21(57), 8749-8758 (2002).
19. Waghray A, Feroze F, Schober MS et al. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 1 (10), 1327-1338 (2001).
20. Xu LL, Su YP, Labiche R et al. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int. J. Cancer 92(3), 322-328 (2001).
21. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 88(7), 2972-2982 (2003).
22. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 20(3-4), 207-223 (2001).
23. Zhang L, Johnson M, Le KH et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res. 63(15 , 4552-4560 (2003).
24. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62(4), 1008-1013 (2002).
25. Mohler JL, Gregory CW, Ford OH III et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10(2), 440-448 (2004).
26. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst. 93(22), 1687-1697 (2001).
27. Brinkmann AO. Molecular basis of androgen insensitivity. Mol. Cell Endocrinol. 179(1-2), 105-109 (2001).
28. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res. 60(4), 944-949 (2000).
29. Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc. Natl Acad. Sci USA 89(14), 6319-6323 (1992).
30. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2(2), 277-285 (1996).
31. Thompson J, Hyytinen ER, Haapala K et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab. Invest. 83(12), 1709-1713 (2003).
32. Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab. Invest. 81(12), 1647-1651 (2001).
33. Hyytinen ER, Haapala K, Thompson J et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab. Invest. 82(11), 1591-1598 (2002).
34. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332(21), 1393-1398 (1995).
35. Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59 (11), 2511-2515 (1999).
36. Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 21(14), 2673-2678 (2003).
37. Nazareth LV, Stenoien DL, Bingman WE III et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol. Endocrinol. 13(12), 2065-2075 (1999).
38. James AJ, Agoulnik IU, Harris JM et al. A novel androgen receptor mutant, A748T. exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol. Endocrinol. 16(12), 2692-2705 (2002).
39. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 23(6), 527-533 (2004).
40. Buchanan G, Greenberg NM, Scher HI et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res. 7(5), 1273-1281 (2001).
41. Zhao XY, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Med. 6(6), 703-706 (2000).
42. Culig Z, Hobisch A, Cronauer MV et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7(12), 1541-1550 (1993).
43. Culig Z, Stober J, Gast A et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect. Prev. 20(1), 68-75 (1996).
44. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J. Endocrinol. 151(1), 1-11 (1996).
45. Veldscholte J, Ris-Stalpers C, Kuiper GG et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Commun. 173(2), 534-540 (1990).
46. Buchanan G, Yang M, Harris JM et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 15(1), 46-56 (2001).
47. Ceraline J, Cruchant MD, Erdmann E et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int. J. Cancer 108(1), 152-157 (2004).
48. Linja MJ, Savinainen KJ, Saramaki OR et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61(9), 3550-3555 (2001).
49. Latil A, Bieche I, Vidaud D et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61(5), 1919-1926 (2001).
50. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89(3), 552-556 (2003).
51. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to anti-androgen therapy. Nature Med. 10(1), 33-39 (2004).
52. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9(4), 401-406 (1995).
53. Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59(4), 803-806 (1999).
54. Ford OH III, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 170(5), 1817-1821 (2003).
55. Dai JL, Burnstein KL. Two androgen response elements in the androgen receptor coding region are required for cell-specific upregulation of receptor messenger RNA. Mol. Endocrinol. 10(12), 1582-1594 (1996).
56. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23(30), 5175-5184 (2004).
57. Johnston SR, Head J, Pancholi S et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 9 (1 Pt 2), 524S-532S (2003).
58. Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54(20), 5474-5478 (1994).
59. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350), 563-566 (1998).
60. Signoretti S, Montironi R, Manola J et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 92(23), 1918-1925 (2000).
61. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. 5(3), 280-285 (1999).
62. Yeh S, Lin HK, Kang HY et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAPK in prostate cancer cells. Proc. Natl Acad. Sci USA 96(10), 5458-5463 (1999).
63. Wen Y, Hu MC, Makino K et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60(24), 6841-6845 (2000).
64. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63(8), 1981-1989 (2003).
65. Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58(20), 4640-4645 (1998).
66. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22(39), 7981-7988 (2003).
67. 1 in patients with metastatic prostatic carcinoma. J. Urol. 161(1), 182-187 (1999).
68. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41(2), 127-133 (1999).
69. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 164(3 Pt 1), 722-725 (2000).
70. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277(9), 7076-7085 (2002).
71. Chen T, Wang LH, Farrar WL. Interleukin-6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60(8), 2132-2135 (2000).
72. Kim O, Jiang T, Xie Y et al. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23(10), 1838-1844 (2004).
73. Culig 2, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell Endocrinol. 197(1-2), 231-238 (2002).
74. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25(2), 276-308 (2004).
75. Hobisch A, Ramoner R, Fuchs D et al. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin. Cancer Res. 7(9), 2941-2948 (2001).
76. Steiner H, Godoy-Tundidor S, Rogatsch H et al. Accelerated in vivo growth of prostate tumors that upregulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Pathol 162(2), 655-663 (2003).
77. Gioeli D, Ficarro SB, Kwiek JJ et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277(32), 29304-29314 (2002).
78. Fu M, Wang C, Reutens AT et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275(27), 20853-20860 (2000).
79. Poukka H, Karvonen U, Janne OA, Palvimo JJ. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl Acad. Sci. USA 97(26), 14145-14150 (2000).
80. Fu M, Wang C, Wang J et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and transrepression function. Mol. Cell Biol. 22(10), 3373-3388 (2002).
81. Gregory CW, Fei X, Panguta LA et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279(8), 7119-7130 (2004).
82. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin-6. Cancer Res. 62(20), 5632-5636 (2002).
83. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61(11), 4315-4319 (2001).
84. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9(1 Pt 2), 447S-454S (2003).
85. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295(5564), 2465-2468 (2002).
86. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5(3), 207-213 (2004).
87. Berrevoets CA, Umar A, Trapman J, Brinkmann AO. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem. J. 379(3), 731-738 (2004).
88. Song LN, Coghlan M, Gelmann EP. Anti-androgen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18(1), 70-85 (2004).
89. Berrevoets CA, Umar A, Brinkmann AO. Anti-androgens: selective androgen receptor modulators. Mol. Cell Endocrinol. 198(1-2), 97-103 (2002).
90. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: an overview of United States trials. J. Urol. 171(2 Pt 2), S5-S8 (2004).
91. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl J. Med. 349(3), 215-224 (2003).
92. Andriole GL, Humphrey P, Ray P et al. Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 172(3), 915-919 (2004).
93. Marhefka CA, Gao W, Chung K et al. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 47(4), 993-998 (2004).
94. Bohl CE, Chang C, Mohler ML et al. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J. Med. Chem. 47(15), 3765-3776 (2004).
95. Gao W, Kearbey JD, Nair VA et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator (SARM), the 5α-reductase inhibitor finasteride, and the anti-androgen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia (BPH). Endocrinology 12(12) 5420-5428 (2004).
96. Yin D, Gao W, Kearbey JD et al. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304(3), 1334-1340 (2003).